Ex vivo inhibition of PGE2 formation in human blood by four bicyclico [3.2.1] octane neolignans isolated from Aniba firmula bark, two with unusual structural pattern

Nat Prod Res. 2024 Jan-Feb;38(3):393-401. doi: 10.1080/14786419.2022.2124248. Epub 2022 Sep 15.

Abstract

The phytochemical investigation of the stem bark crude extract of Aniba firmula (Lauraceae) led to the isolation of undescribed bicyclic [3.2.1] octane neolignans, 1 and 2, characterized by unusual bicyclic patterns and two other known bicyclic neolignans 3 and 4. Anti-inflammatory bicyclic [3.2.1] octane neolignans metabolites were previously reported in the literature, and the A. firmula stands out in the Lauraceae family as a source of potentially bioactive compounds. Thus, herein the anti-inflammatory potential of four isolated compounds from A. firmula was accessed via an ex vivo anti-inflammatory model that included plasmatic quantification of the prostaglandin E2 (PGE2) inflammatory mediator. Compounds 2 and 3 exhibited significant anti-inflammatory activity by inhibiting the production of PGE2 in plasma samples, thus by interference with the cyclooxygenase (COX) inflammatory pathway. Therefore, these findings demonstrate that the bicyclic octane neolignan classes [3.2.1] can present anti-inflammatory potential.

Keywords: Aniba firmula; Neolignan; bicyclic [3.2.1] octane; prostaglandin E2.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Cyclooxygenase 2
  • Dinoprostone
  • Humans
  • Lauraceae* / chemistry
  • Lignans* / chemistry
  • Lignans* / pharmacology
  • Octanes
  • Plant Bark

Substances

  • Lignans
  • Dinoprostone
  • octane
  • Octanes
  • Anti-Inflammatory Agents
  • Cyclooxygenase 2